Raphael Landovitz, MD
Dr. Landovitz is an internationally recognized authority on HIV pre- and post-exposure prophylaxis, with contributions to the implementation science of early oral PrEP options, and the development of next-generation HIV PrEP agents and strategies, including the registrational trials supporting long-acting injectable PrEP. He has served on scientific leadership committees for the DAIDS-funded AIDS Clinical Trials Group, the NICHD-funded Adolescent Trials Network, and currently serves on the executive committee of the HIV Prevention Trials Network. Dr. Landovitz has published and held grants on the HIV therapeutics and HIV prevention, including the intersection of behavioral/social science and the optimal use of antiviral agents for both treatment and prevention. He will help guide the CFAR with his expertise in HIV biomedical prevention.